Opus Genetics, Inc. announced that Dr. Ashwath Jayagopal will transition from his role as Chief Scientific and Development Officer effective October 19, 2026. The company entered into a separation and release agreement with Dr. Jayagopal, which includes a six-month consulting arrangement for transition services at a rate of $250 per hour. His outstanding vested options remain exercisable during the consulting term. Opus Genetics is a clinical-stage biotechnology company focused on developing genetic therapies.
